Refined cytogenetic IPSS‐R evaluation by the use of SNP array in a cohort of 290 MDS patients
Genes, Chromosomes and Cancer · 2023
DOI: 10.1002/gcc.23191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2023. Verfasst von Ilaria Scarpelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncogenomic laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Chromosome Aberrations, Myelodysplastic Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Genetic testing plays a central role in myelodysplastic neoplasms (MDS) diagnosis, prognosis, and therapeutic decisions. The widely applied cytogenetic revised international prognostic scoring system (IPSS‐R) was based on chromosome banding analysis (CBA). However, subsequently developed genetic methodologies, such as single nucleotide polymorphism (SNP) array, demonstrated to be a valid alternative test for MDS. SNP array is, in fact, able to detect the majority of MDS‐associated cytogenetic aberrations, by providing further genomic information due to its higher resolution. In this study, 290 samples from individuals with a confirmed or suspected diagnosis of MDS were tested by both CBA and SNP array, in order to evaluate and compare their cytogenetic IPSS‐R score in the largest MDS cohort reported so far. A concordant or better refined cytogenetic IPSS‐R array‐based score was obtained for 95% of cases (277). Therefore, this study confirms the effective applicability of SNP array toward the cytogenetic IPSS‐R evaluation and consequently, toward the molecular international prognostic scoring system for MDS (IPSS‐M) assessment, which ensures an improved MDS risk stratification refinement. Considering the advent of additional genetic technologies interrogating the whole genome with increased resolutions, counting cytogenetic abnormalities based on their size may result in a simplistic approach. On the contrary, assessing overall genomic complexity may provide additional crucial information. Independently of the technology used, genetic results should indeed aim at ensuring a highly refined stratification for MDS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncogenomic laboratory, Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
- Hematology Service and Central Laboratory of Hematology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Hematology Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Ilaria Scarpelli
Zitieren
APA
Scarpelli, I., Stalder, V. B., Tsilimidos, G., Rapakko, K., Costanza, M., Blum, S., & Schoumans, J. (2023). Refined cytogenetic IPSS‐R evaluation by the use of SNP array in a cohort of 290 MDS patients. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23191
Vancouver
Scarpelli I, Stalder VB, Tsilimidos G, Rapakko K, Costanza M, Blum S, et al. Refined cytogenetic IPSS‐R evaluation by the use of SNP array in a cohort of 290 MDS patients. Genes, Chromosomes and Cancer. 2023. doi:10.1002/gcc.23191
BibTeX
@article{Scarpelli2023,
author = {Scarpelli, Ilaria and Stalder, Valérie Beyer and Tsilimidos, Gerasimos and Rapakko, Katrin and Costanza, Mariangela and Blum, Sabine and Schoumans, Jacqueline},
title = {Refined cytogenetic IPSS‐R evaluation by the use of SNP array in a cohort of 290 MDS patients},
journal = {Genes, Chromosomes and Cancer},
year = {2023},
doi = {10.1002/gcc.23191}
}
EUVIMED